Outcomes Research in Review

Low-Intensity PSA-Based Screening Did Not Reduce Prostate Cancer Mortality


 

References

Applications for Clinical Practice

PSA test as a diagnostic tool for prostate cancer has significant drawbacks, and population screening strategies using this test will need to grapple with issues of misdiagnosis, overdiagnosis, and treatment that can have potential harmful consequences. The alternative of not screening is that prostate cancer may be diagnosed at later stages and more men may suffer morbidity and mortality from the disease. A better test and screening strategy are needed to balance the benefits and harms of screening so that older men may benefit from early diagnosis of prostate cancer.

Pages

Recommended Reading

HIPEC for Ovarian Cancer: Standard of Care or Experimental Approach?
Journal of Clinical Outcomes Management
Hospitalizations for fracture in patients with metastatic disease: primary source lesions in the United States
Journal of Clinical Outcomes Management
Mortality estimates put pancreatic cancer on the map
Journal of Clinical Outcomes Management
VIDEO: U.S. melanoma incidence hits all-time high
Journal of Clinical Outcomes Management
CAR T-Cell Therapy Shows High Levels of Durable Response in Refractory Large B-Cell Lymphoma
Journal of Clinical Outcomes Management
Coming soon: CAR T-cell approvals in multiple myeloma
Journal of Clinical Outcomes Management
Integrating survivorship care planning in radiation oncology workflow
Journal of Clinical Outcomes Management
Enhancing communication between oncology care providers and patient caregivers during hospice
Journal of Clinical Outcomes Management
Qualitative assessment of organizational barriers to optimal lung cancer care in a community hospital setting in the United States
Journal of Clinical Outcomes Management
Five-year survival for non-Hodgkin lymphoma tops 71%
Journal of Clinical Outcomes Management